首页> 美国卫生研究院文献>Translational Psychiatry >Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients
【2h】

Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients

机译:遗传和后生生物标志物利培酮治疗中国汉族精神分裂症患者的联合研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia. However, partially affected by genetic or environmental factors, there is significant difference in treatment outcomes among patients. In this study, we aimed to interpret the difference between good and poor responders treated with risperidone in both genetic and epigenetic levels in 288 mainland Chinese patients. We recruited a Henan cohort including 98 patients as initial discovery group and then confirmed our results in Shanghai cohort. In genetic studies, we found 10 candidate single-nucleotide polymorphisms (SNPs) and 2 rare variants in Henan cohort by next-generation sequencing of 100 risperidone-response-related genes. After replication in Shanghai cohort by massarray platform, ultimately, rs6706232 and rs4818 were significantly associated with risperidone response in the two cohort meta-analysis (P=0.024 and 0.04, respectively). Besides, we also selected another reported 17 candidate SNPs associated with risperidone drug response to replicate in our mainland Chinese samples, while, we found no significant SNPs after Bonferroni correction. In epigenetic studies, we investigated the methylation status in promoters or gene-coding region of risperidone drug response-related genes including CYP3A4, CYP2D6, ABCB1, HTR2A, DRD2. Totally we found seven significant CpG sites in the meta-analysis with Bonferroni-corrected PCYP3A4_CpG_-36=0.0014, PCYP3A4_CpG_-258=0.0013, PCYP3A4_CpG_-296=0.0014, PCYP3A4_CpG_-367:-372:-374=0.028, PCYP2D6_CpG_193=0.012, PCYP2D6_CpG_242:244:250=0.00076 and PCYP2D6_CpG_284=0.034, respectively. As genetic and epigenetic factors may interactively affect drug response, we finally carried out a multivariant interaction analysis with multifactor dimensionality reduction and discovered a significant four-locus model (CYP3A4_CpG_-82:-86 +rs6280+rs1800497+rs6265, P=0.038) affecting drug response. These findings could partially explain different risperidone response outcome in Chinese population in a systematic level.
机译:如今,利培酮是一种非典型的抗精神病药物,已越来越多地用于精神分裂症的治疗和维持治疗。然而,部分地受遗传或环境因素影响的患者之间的治疗结果存在显着差异。在这项研究中,我们旨在解释在288名中国大陆患者中,使用利培酮治疗的好反应者和差反应者在遗传和表观遗传水平上的差异。我们招募了包括98名患者在内的河南队列作为初始发现组,然后在上海队列中证实了我们的结果。在遗传研究中,我们通过对100个与利培酮反应相关基因进行下一代测序,发现了10个候选单核苷酸多态性(SNP)和2个罕见变体在河南队列中。在上海队列中通过质谱阵列进行复制后,最终,在两个队列荟萃分析中,rs6706232和rs4818与利培酮反应显着相关(分别为P = 0.024和0.04)。此外,我们还选择了另一种报告的与利培酮药物反应有关的候选SNPs在我们的中国大陆样本中复制,而Bonferroni校正后未发现明显的SNPs。在表观遗传学研究中,我们调查了利培酮药物反应相关基因(包括CYP3A4,CYP2D6,ABCB1,HTR2A,DRD2)的启动子或基因编码区中的甲基化状态。共发现与荟萃分析7个显著CpG位点邦费罗尼校正PCYP3A4_CpG_-36 = 0.0014,PCYP3A4_CpG_-258 = 0.0013,PCYP3A4_CpG_-296 = 0.0014,PCYP3A4_CpG_-367:-372:-374 = 0.028,PCYP2D6_CpG_193 = 0.012, P CYP2D6 _CpG_242:244:250 = 0.00076和 P CYP2D6 _CpG_284 = 0.034。由于遗传因素和表观遗传因素可能相互作用地影响药物反应,因此我们最终进行了具有多因素维度降低的多变量相互作用分析,发现了一个重要的四基因座模型( CYP3A4 _CpG_-82:-86 + rs6280 + rs1800497 + rs6265, P = 0.038)影响药物反应。这些发现可以部分系统地解释中国人群中利培酮反应的不同结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号